Cargando…

Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients

OBJECTIVE: To profile clinically non‐aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, microRNAs (miRNA)/long noncoding RNA (...

Descripción completa

Detalles Bibliográficos
Autores principales: Guaraldi, Federica, Morandi, Luca, Zoli, Matteo, Mazzatenta, Diego, Righi, Alberto, Evangelisti, Stefania, Ambrosi, Francesca, Tonon, Caterina, Giannini, Caterina, Lloyd, Ricardo V., Asioli, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828656/
https://www.ncbi.nlm.nih.gov/pubmed/36161330
http://dx.doi.org/10.1111/cen.14827
_version_ 1784867315518537728
author Guaraldi, Federica
Morandi, Luca
Zoli, Matteo
Mazzatenta, Diego
Righi, Alberto
Evangelisti, Stefania
Ambrosi, Francesca
Tonon, Caterina
Giannini, Caterina
Lloyd, Ricardo V.
Asioli, Sofia
author_facet Guaraldi, Federica
Morandi, Luca
Zoli, Matteo
Mazzatenta, Diego
Righi, Alberto
Evangelisti, Stefania
Ambrosi, Francesca
Tonon, Caterina
Giannini, Caterina
Lloyd, Ricardo V.
Asioli, Sofia
author_sort Guaraldi, Federica
collection PubMed
description OBJECTIVE: To profile clinically non‐aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, microRNAs (miRNA)/long noncoding RNA (LncRNA)‐post‐transcriptional regulators and therapy targets. DESIGN: Retrospective observational study. PATIENTS AND MEASUREMENTS: A total of 64 non‐aggressive and 41 aggressive PAs/PitNETs and 6 pituitary carcinomas treated by endoscopic surgery with ≥1‐year follow‐up were included. Somatic mutations of 17 genes and DNA methylation of 22 genes were assessed. Ten normal pituitaries were used as control. RESULTS: We found at least one mutation in 17 tumours, including 6/64 non‐aggressive, 10/41 aggressive PAs/PitNETs, and 1/6 pituitary carcinoma. AIP (N = 6) was the most frequently mutated gene, followed by NOTCH (4), and TP53 (3). Hypermethylation of PARP15, LINC00599, ZAP70 was more common in aggressive than non‐aggressive PAs/PITNETs (p < .05). Lower levels of methylation of AIP, GNAS and PDCD1 were detected in aggressive PAs/PITNETs than non‐aggressive ones (p < .05). For X‐linked genes, males presented higher level of methylation of FLNA, UXT and MAGE family (MAGEA11, MAGEA1, MAGEC2) genes in aggressive vs. non‐aggressive PAs/PITNETs (p < .05). In pituitary carcinomas, methylation of autosomal genes PARP15, LINC00599, MIR193 and ZAP70 was higher than in PAs/PITNETs, while X‐linked genes methylation level was lower. CONCLUSIONS: Somatic mutations and methylation levels of genes involved in cell proliferation/differentiation, miRNA/LncRNA‐post‐transcriptional regulators and targets of antineoplastic therapies are different in non‐aggressive and in aggressive PAs/PitNETs. Methylation profile also varies according to gender. Combined genetic‐epigenetic analysis, in association with clinico‐radiological‐pathological data, may be of help in predicting PA/PitNET behaviour.
format Online
Article
Text
id pubmed-9828656
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98286562023-01-10 Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients Guaraldi, Federica Morandi, Luca Zoli, Matteo Mazzatenta, Diego Righi, Alberto Evangelisti, Stefania Ambrosi, Francesca Tonon, Caterina Giannini, Caterina Lloyd, Ricardo V. Asioli, Sofia Clin Endocrinol (Oxf) ORIGINAL ARTICLES OBJECTIVE: To profile clinically non‐aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, microRNAs (miRNA)/long noncoding RNA (LncRNA)‐post‐transcriptional regulators and therapy targets. DESIGN: Retrospective observational study. PATIENTS AND MEASUREMENTS: A total of 64 non‐aggressive and 41 aggressive PAs/PitNETs and 6 pituitary carcinomas treated by endoscopic surgery with ≥1‐year follow‐up were included. Somatic mutations of 17 genes and DNA methylation of 22 genes were assessed. Ten normal pituitaries were used as control. RESULTS: We found at least one mutation in 17 tumours, including 6/64 non‐aggressive, 10/41 aggressive PAs/PitNETs, and 1/6 pituitary carcinoma. AIP (N = 6) was the most frequently mutated gene, followed by NOTCH (4), and TP53 (3). Hypermethylation of PARP15, LINC00599, ZAP70 was more common in aggressive than non‐aggressive PAs/PITNETs (p < .05). Lower levels of methylation of AIP, GNAS and PDCD1 were detected in aggressive PAs/PITNETs than non‐aggressive ones (p < .05). For X‐linked genes, males presented higher level of methylation of FLNA, UXT and MAGE family (MAGEA11, MAGEA1, MAGEC2) genes in aggressive vs. non‐aggressive PAs/PITNETs (p < .05). In pituitary carcinomas, methylation of autosomal genes PARP15, LINC00599, MIR193 and ZAP70 was higher than in PAs/PITNETs, while X‐linked genes methylation level was lower. CONCLUSIONS: Somatic mutations and methylation levels of genes involved in cell proliferation/differentiation, miRNA/LncRNA‐post‐transcriptional regulators and targets of antineoplastic therapies are different in non‐aggressive and in aggressive PAs/PitNETs. Methylation profile also varies according to gender. Combined genetic‐epigenetic analysis, in association with clinico‐radiological‐pathological data, may be of help in predicting PA/PitNET behaviour. John Wiley and Sons Inc. 2022-10-07 2022-12 /pmc/articles/PMC9828656/ /pubmed/36161330 http://dx.doi.org/10.1111/cen.14827 Text en © 2022 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Guaraldi, Federica
Morandi, Luca
Zoli, Matteo
Mazzatenta, Diego
Righi, Alberto
Evangelisti, Stefania
Ambrosi, Francesca
Tonon, Caterina
Giannini, Caterina
Lloyd, Ricardo V.
Asioli, Sofia
Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
title Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
title_full Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
title_fullStr Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
title_full_unstemmed Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
title_short Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
title_sort epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828656/
https://www.ncbi.nlm.nih.gov/pubmed/36161330
http://dx.doi.org/10.1111/cen.14827
work_keys_str_mv AT guaraldifederica epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT morandiluca epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT zolimatteo epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT mazzatentadiego epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT righialberto epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT evangelististefania epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT ambrosifrancesca epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT tononcaterina epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT gianninicaterina epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT lloydricardov epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients
AT asiolisofia epigenomicandsomaticmutationsofpituitarytumorswithclinicalandpathologicalcorrelationsin111patients